Physician profile
John E Carter
NPI 1851326086
$7,155.99
in general payments reported to CMS, 2019-2025
55 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,720 · 2020: $630 · 2021: $1,050 · 2022: $720 · 2023: $1,041 · 2024: $927 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $988.31 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $607.84 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $443.61 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $418.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $387.83 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.78 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.95 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Otsuka America Pharmaceutical, INC. | $280.03 | 2019-2025 | Rexulti |
| Allergan, INC. | $258.54 | 2019-2020 | |
| Glaxosmithkline, LLC. | $256.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $223.77 | 2019-2023 | Dificid |
| Corium, LLC | $212.52 | 2022-2025 | Azstarys, Adlarity |
| Exact Sciences Corporation | $191.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $152.95 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $136.34 | 2021-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.